10-K: Goldenwell Biotech Inc. Files 10-K Annual Report, Cites Going Concern Uncertainty

Goldenwell Biotech's 2023 annual report reveals ongoing losses and a dependence on future financing, raising concerns about the company's ability to continue as a going concern.

Summary

• Goldenwell Biotech, incorporated in 2019, is a development-stage company focused on nutraceutical and dietary supplements.
• The company reported revenues of $2,340 for 2023, a significant decrease from $47,800 in 2022.
• Goldenwell incurred a net loss of $116,895 in 2023, compared to a net loss of $985,097 in 2022.
• As of December 31, 2023, the company had cash and cash equivalents of $54,231 and a working capital balance of $84,723.
• The company's ability to continue as a going concern is dependent on raising capital and achieving profitable operations.
• Goldenwell has exclusive license agreements for its technology, expiring in 2025, with entities controlled by its directors.
• The company has completed initial marketing analysis, research and development, and parts of production for its five products, but needs to construct manufacturing facilities and train a workforce.
• Goldenwell estimates it needs $5,000,000 and one year to complete manufacturing setup.
• The company's shares are traded on the OTC Pink tier under the symbol GWLL.
• As of March 29, 2024, there were 99,000,000 shares of common stock outstanding.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including low revenue, ongoing losses, and a dependence on future financing. The going concern warning and ineffective internal controls further contribute to a negative sentiment.

Positives

• The company significantly reduced its net loss from $985,097 in 2022 to $116,895 in 2023.
• The company has completed initial marketing analysis, research and development, and parts of production for its products.
• The company has exclusive license agreements for its technology.

Negatives

• The company's revenue decreased substantially from $47,800 in 2022 to $2,340 in 2023.
• The company has incurred recurring losses from operations and has little revenue.
• The company's ability to continue as a going concern is dependent on raising capital.
• The company needs an estimated $5,000,000 to complete manufacturing facilities.
• The company's internal controls over financial reporting were deemed ineffective.
• The company has no independent directors on its board.

Risks

• The company's ability to continue as a going concern is dependent on raising capital, which is not guaranteed.
• The company has incurred recurring losses from operations and has little revenue.
• The company's exclusive license agreements expire in 2025.
• The company needs to construct manufacturing facilities and train a workforce, requiring significant capital.
• The company's internal controls over financial reporting were deemed ineffective.
• The company's shares may be subject to penny stock regulations, which could restrict trading.
• The company has no independent directors on its board, which could lead to conflicts of interest.

Future Outlook

The company plans to increase sales of its products and believes it can satisfy its cash requirements through the fiscal year end of December 31, 2023, from its cash of $54,231. The company also plans to raise additional funds through debt or equity offerings.

Management Comments

• Management believes that the continuing financial support from the existing shareholders and external financing will provide the additional cash to meet our obligations as they become due.
• Management estimates that we need approximately $5,000,000 to complete such activities and that it would take approximately one year to complete such activities.

Industry Context

The company operates in the nutraceutical and dietary supplement industry, which is competitive and subject to changing consumer preferences and regulatory requirements. The company's reliance on licensed technology and its need for significant capital to establish manufacturing facilities are common challenges for early-stage companies in this sector.

Comparison to Industry Standards

• Goldenwell's revenue of $2,340 is significantly lower than established companies in the nutraceutical and dietary supplement industry, which often report millions or billions in annual revenue.
• The company's net loss of $116,895, while improved from the previous year, is still indicative of an early-stage company that has not yet achieved profitability, which is common for companies in this phase.
• The company's cash position of $54,231 is very low compared to industry standards, where companies typically have much larger cash reserves to fund operations and growth.
• The company's reliance on licensed technology is a common practice in the industry, but the short term of the licenses (expiring in 2025) is a risk factor.
• The lack of independent directors and ineffective internal controls are significant deviations from industry best practices for public companies.

Corporate Governance

Related Party Transactions

• The company purchased inventory of $103,125 from Australian Trefoil Heath Technology, which is owned by Li, Yang, the Treasurer of the Company.
• The company borrowed a long-term loan from Shuang Liu, the Chief Executive Officer of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity financing.
• The company's ability to continue as a going concern is uncertain, which could impact all stakeholders.
• Employees are not mentioned, but the company's financial situation could affect future hiring and job security.
• Customers may be impacted by the company's ability to bring products to market.
• Suppliers and creditors face the risk of non-payment if the company fails to secure additional financing.

Next Steps

• The company plans to increase the sales of its products.
• The company needs to construct manufacturing facilities and train a workforce.
• The company plans to raise additional funds through debt or equity offerings.

Key Dates

Keywords

biotech, nutraceuticals, dietary supplements, financial results, going concern, capital raise, license agreements, manufacturing, OTC Pink, internal controls